{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T01:59:34Z","timestamp":1783216774977,"version":"3.54.6"},"reference-count":45,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of the Basque Country UPV\/EHU","award":["GIU17\/32"],"award-info":[{"award-number":["GIU17\/32"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Tedizolid and linezolid have antibacterial activity against the most important acute bacterial skin and skin-structure infection (ABSSSIs) pathogens. The objective of this work was to apply PK\/PD analysis to evaluate the probability of attaining the pharmacodynamic target of these antimicrobials based on the susceptibility patterns of different clinical isolates causing ABSSSI. Pharmacokinetic and microbiological data were obtained from the literature. PK\/PD breakpoints, the probability of target attainment (PTA) and the cumulative fraction of response (CFR) were calculated by Monte Carlo simulation. PTA and CFR are indicative of treatment success. PK\/PD breakpoints of tedizolid and linezolid were 0.5 and 1 mg\/L, respectively. Probability of treatment success of tedizolid was very high (&gt;90%) for most staphylococci strains, including MRSA and coagulase-negative staphylococci (CoNS). Only for methicillin- and linezolid-resistant S. aureus (MLRSA) and linezolid resistant (LR) CoNS strains was the CFR of tedizolid very low. Except for LR, daptomycin-non-susceptible (DNS), and vancomycin-resistant (VRE) E. faecium isolates, tedizolid also provided a high probability of treatment success for enterococci. The probability of treatment success of both antimicrobials for streptococci was always higher than 90%. In conclusion, for empiric treatment, PK\/PD analysis has shown that tedizolid would be adequate for most staphylococci, enterococci, and streptococci, even those LR whose linezolid resistance is mediated by the cfr gene.<\/jats:p>","DOI":"10.3390\/antibiotics10070755","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T13:02:10Z","timestamp":1624366930000},"page":"755","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetic\/Pharmacodynamic Analysis of Tedizolid Phosphate Compared to Linezolid for the Treatment of Infections Caused by Gram-Positive Bacteria"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-6385","authenticated-orcid":false,"given":"Alicia","family":"Rodr\u00edguez-Gasc\u00f3n","sequence":"first","affiliation":[{"name":"Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country UPV\/EHU, 01006 Vitoria-Gasteiz, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Bioaraba, 01009 Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Aguirre-Qui\u00f1onero","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Bioaraba, 01009 Vitoria-Gasteiz, Spain"},{"name":"Microbiology Service, Araba University Hospital, Osakidetza Basque Health Service, 01009 Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-0775","authenticated-orcid":false,"given":"Mar\u00eda Angeles Solin\u00eds","family":"Aspiazu","sequence":"additional","affiliation":[{"name":"Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country UPV\/EHU, 01006 Vitoria-Gasteiz, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Bioaraba, 01009 Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-9906","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Canut-Blasco","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Bioaraba, 01009 Vitoria-Gasteiz, Spain"},{"name":"Microbiology Service, Araba University Hospital, Osakidetza Basque Health Service, 01009 Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/17512433.2020.1774362","article-title":"Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections","volume":"13","author":"Carena","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Singh, K.V., Arias, C.A., and Murray, B.E. (2019). Efficacy of Tedizolid against Enterococci and Staphylococci, Including cfr + Strains, in a Mouse Peritonitis Model. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02627-18"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/QCO.0000000000000439","article-title":"The role of tedizolid in skin and soft tissue infections","volume":"31","author":"Bouza","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","unstructured":"European Medicines Agency (2021, June 14). Sivextro, EPAR\u2014Product Information. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002846\/WC500184802.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"ref_8","first-page":"9274","article-title":"Research progress on the oxazolidinone drug linezolid re-sistance","volume":"24","author":"Liu","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jhin.2019.10.013","article-title":"Long-term endemic situation caused by a linezolid- and meticillin-resistant clone of Staphylococcus epidermidis in a tertiary hospital","volume":"105","author":"Rodicio","year":"2020","journal-title":"J. Hosp. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs. linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lan, S.-H., Lin, W.-T., Chang, S.-P., Lu, L.-C., Chao, C.-M., Lai, C.-C., and Wang, J.-H. (2019). Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis. Antibiotics, 8.","DOI":"10.3390\/antibiotics8030137"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14740338.2018.1446939","article-title":"Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections","volume":"17","author":"Hardalo","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"Isla","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/cid\/cit615","article-title":"Use of Pharmacokinetic\/Pharmacodynamic Systems Analyses to Inform Dose Selection of Tedizolid Phosphate","volume":"58","author":"Lodise","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.inf.0000094940.81959.14","article-title":"Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation","volume":"22","author":"Bradley","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jac\/dkaa005","article-title":"Methodological features of clinical pharmacokinetic\u2013pharmacodynamic studies of antibacterials and antifungals: A systematic review","volume":"75","author":"McAleenan","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","unstructured":"EMA-CHMP (2016). Guideline on the Use of Pharmacokinetics and Pharmacodynamics in the Development of Antimicrobial Medicinal Products, EMA\/CHMP\/594085\/2015."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1128\/AAC.03423-14","article-title":"Tedizolid Population Pharmacokinetics, Exposure Response, and Target Attainment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","unstructured":"(2021, June 14). Linezolid: Rationale for the EUCAST Clinical Breakpoints, Version 1.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_21","unstructured":"(2021, June 14). Tedizolid: Rationale for EUCAST Clinical Breakpoints, Version 1.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.diagmicrobio.2014.08.011","article-title":"Results of the Surveillance of Tedizolid Activity and Resistance Program: In vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe","volume":"81","author":"Sahm","year":"2015","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12941-014-0046-0","article-title":"Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone","volume":"13","author":"Zurenko","year":"2014","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_24","first-page":"167","article-title":"In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci","volume":"67","author":"Culebras","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/1120009X.2019.1609740","article-title":"Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014\u20132015)","volume":"31","author":"Pfaller","year":"2019","journal-title":"J. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jac\/dkv302","article-title":"Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid","volume":"71","author":"Barber","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","first-page":"255","article-title":"Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: An in vitro comparison","volume":"29","author":"Candel","year":"2016","journal-title":"Rev. Espanola Quimioter. Publicacion Soc. Espanola Quimioter."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s10096-016-2747-0","article-title":"Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates","volume":"35","author":"Klupp","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2147\/IDR.S202789","article-title":"In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae","volume":"12","author":"Hipp","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_30","unstructured":"(2021, June 14). The European Committee on Antimicrobial Susceptibility Testing\u2014EUCAST Clinical Breakpoints-Bacteria (v 11.0). Available online: https:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/DDDT.S30728","article-title":"Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections","volume":"7","author":"Grau","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijantimicag.2012.06.005","article-title":"Comparison of antimicrobial pharmacokinetic\/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria","volume":"40","author":"Isla","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_33","first-page":"121","article-title":"Application of pharmacokinetic\/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine","volume":"32","author":"Isla","year":"2019","journal-title":"Rev. Esp. Quimioter. Publ. Soc. Esp. Quimioter."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eimc.2018.10.013","article-title":"Pharmacokinetic\/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients","volume":"37","author":"Valero","year":"2019","journal-title":"Enferme. Infecc. Microbiol. Cl\u00edn."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"i67","DOI":"10.1093\/jac\/dkt028","article-title":"Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD)","volume":"68","author":"Zelenitsky","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: The EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vinks, A.A., Derendorf, H., and Mouton, J.W. (2014). Setting clinical MIC breakpoints from a PK\/PD point of view: It is the dose that matters. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics, Springer.","DOI":"10.1007\/978-0-387-75613-4"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2018.01.006","article-title":"An in vitro evaluation of the efficacy of tedizolid: Implications for the treatment of skin and soft tissue infections","volume":"91","author":"Delpech","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/jac\/dky188","article-title":"Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: Results from the SENTRY Antimicrobial Surveillance Program","volume":"73","author":"Deshpande","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105977","DOI":"10.1016\/j.ijantimicag.2020.105977","article-title":"Interregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes","volume":"55","author":"Moure","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/dkm536","article-title":"Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic\u2013pharmacodynamic models with Monte Carlo simulation","volume":"61","author":"Frei","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/phar.1491","article-title":"Early Experience with Tedizolid: Clinical Efficacy, Pharmacodynamics, and Resistance","volume":"34","author":"Rybak","year":"2014","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2004.08.019","article-title":"Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae","volume":"51","author":"Owens","year":"2005","journal-title":"Diagn Microbiol. Infect Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: An update","volume":"55","author":"Mouton","year":"2005","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/7\/755\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:21:02Z","timestamp":1760163662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/7\/755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["antibiotics10070755"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10070755","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}